Enzymotec Ltd (ENZY) reported quarterly earnings results on Tuesday, Aug-9-2016. The company reported $0.04 earnings per share for the quarter, missing the analyst consensus estimate by $-0.03. Analysts had a consensus of $0.07. The company posted revenue of $11.70 million in the period, compared to analysts expectations of $14.90 million. The company’s revenue was down -12.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.11 EPS.
Enzymotec Ltd opened for trading at $8.95 and hit $9.15 on the upside on Monday, eventually ending the session at $9.06, with a gain of 0.55% or 0.05 points. The heightened volatility saw the trading volume jump to 16,472 shares. Company has a market cap of $206 M.
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies research expertise and clinical validation process enable it to develop differentiated solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings. The Company’s clinically-validated products include bio-functional lipid-based compounds designed to address dietary needs medical disorders and common diseases. The Company’s technologies enable it to identify appropriate lipid-modifying enzymes and then improve the activity of these enzymes as well as to enable their use in organic media. These enzymes are then utilized to restructure lipids found in natural sources including krill fish vegetable sources and bovine milk. Its products include InFat Soy-PS PS and GPC Line of Products krill oil Vayarin Vayacog and Vayarol.